Mayo Clinic– tag –
-
Mayo Clinic Leads ARPA-H Initiative to Advance Gene-Editing Therapies for Rare Immune Diseases, Integrating CRISPR and Novel Delivery for Over 500 Inborn Errors of Immunity
Mayo Clinic News Network USA Overview Mayo Clinic is participating in a 5-year collaborative research initiative, funded by an ARPA-H grant, to accelerate the development of gene-editing therapies for rare immune diseases. This initiativ... -
Sana Biotechnology Advances Phase 1 Clinical Trial for Immunosuppression-Free iPSC-Derived Islet Cell Therapy UP421 for Type 1 Diabetes
AAII USA Overview Sana Biotechnology is actively progressing its Phase 1 clinical trial for UP421, an allogeneic islet cell product engineered with its Hypoimmune Platform (HIP) technology for type 1 diabetes, aiming to eliminate the nee... -
Avaí Bio Achieves GMP Milestone for Anti-Aging Cell Therapy; Beam Therapeutics Targets Accelerated Approval for BEAM-302; Sana Partners with Mayo Clinic for Type 1 Diabetes
Newswire.ca Canada Overview Multiple biotech companies reported significant advancements: Avaí Bio completed its GMP-grade Master Cell Bank (MCB) for the α-Klotho anti-aging program, paving the way for preclinical and clinical trials. Be... -
Avaí Bio Establishes GMP-Grade Master Cell Bank for Alpha-Klotho Anti-Aging Program, Advancing Cell Therapy Toward Commercialization
PR Newswire (via USA News Group) USA Overview Avaí Bio has achieved a critical manufacturing milestone by completing its GMP-grade Master Cell Bank (MCB) for the alpha-Klotho anti-aging program. This MCB ensures a high-quality, standardi... -
Sana Biotechnology Reports 14-Month Positive Clinical Results for Immunosuppression-Free iPSC-Derived Islet Cell Transplant in Type 1 Diabetes
Simply Wall St (via Nasdaq:SANA) USA Overview Sana Biotechnology announced continued positive clinical results from its study of iPSC-derived islet cell transplantation (UP421) for Type 1 diabetes, spanning 14 months without immunosuppre...
1